Project Details
| Status | Active |
|---|---|
| Effective start/end date | 10/12/20 → 07/30/26 |
Funding
- Merck Sharp and Dohme Limited Liability Corporation: $93,808.68
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcino
- Loree, Thom (PI)
Project: Research